Literature DB >> 17369719

Phosphate restriction in diet therapy.

Eiji Takeda1, Hironori Yamamoto, Yuka Nishida, Tadatoshi Sato, Naoki Sawada, Yutaka Taketani.   

Abstract

Hyperphosphatemia and hyperparathyroidism, frequently observed in patients with endstage renal disease, are associated with renal osteodystrophy, organ calcification, cardiovascular disease and sudden death. Restriction of dietary protein and phosphorus is beneficial in slowing the progression of renal failure. Dietary phosphorus restriction must be prescribed at all stages of renal failure in adults. It may be achieved by decreasing protein intake and avoiding foods rich in phosphorus. An average of 60-80% of the phosphorus intake is absorbed in the gut in dialysis patients. If phosphate binders are employed, the phosphorus absorbed from the diet may be reduced to 40%. Conventional hemodialysis with a high-flux, high-efficiency dialyzer removes approximately 30 mmol (900 mg) phosphorus during each dialysis performed three times weekly. Therefore, 750 mg of phosphorus intake should be the critical value above which a positive balance of phosphorus may occur. This value corresponds to a protein diet of 45-50 g/day or 0.8 g/kg body weight/day for a 60 kg patient. Target levels should become 9.2-9.6 mg/dl for calcium, 2.5-5.5 mg/dl for phosphorus, <55 mg2/dl2 for the calcium-phosphorus product, and 100-200 pg/ml for intact parathyroid hormone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17369719     DOI: 10.1159/000101004

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  4 in total

Review 1.  Pre-treatment considerations in childhood hypertension due to chronic kidney disease.

Authors:  Wasiu Adekunle Olowu
Journal:  World J Nephrol       Date:  2015-11-06

Review 2.  Dietary interventions for mineral and bone disorder in people with chronic kidney disease.

Authors:  Zhuangzhu Liu; Guobin Su; Xinfeng Guo; Yifan Wu; Xusheng Liu; Chuan Zou; Lei Zhang; Qianchun Yang; Yuan Xu; Weizhong Ma
Journal:  Cochrane Database Syst Rev       Date:  2015-09-16

3.  Phosphates in medications: Impact on dialysis patients
.

Authors:  Dixie-Ann Sawin; Lin Ma; Amanda Stennett; Norma Ofsthun; Rainer Himmele; Robert J Kossmann; Franklin W Maddux
Journal:  Clin Nephrol       Date:  2020-04       Impact factor: 0.975

Review 4.  The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors:  Jacek Rysz; Beata Franczyk; Robert Rokicki; Anna Gluba-Brzózka
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.